General Information of Drug (ID: DMP86R3)

Drug Name
1,3-bis(1,3-benzothiazol-2-ylthio)acetone Drug Info
Synonyms
1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; 1,3-bis(1,3-benzothiazol-2-ylthio)acetone; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409
Indication
Disease Entry ICD 11 Status REF
Glioma 2A00.0 Investigative [1]
Melanoma 2C30 Investigative [1]
Cross-matching ID
PubChem CID
1240423
TTD Drug ID
DMP86R3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting AP endonuclease 1 (APEX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
APX3330 DMU6NBO Diabetic retinopathy 9B71.0 Phase 2 [2]
APX-3330 DMXIMQT Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
5-fluoro-1H-indole-2-carboxylic acid DM9U1HV Glioma 2A00.0 Investigative [1]
3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile DMWLIK1 Glioma 2A00.0 Investigative [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AP endonuclease 1 (APEX1) TTHGL48 APEX1_HUMAN Inhibitor [1]

References

1 Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
2 Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19.
3 Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.